Applications of H-D-Cit-OH in Industrial Manufacturing

As an established producer of H-D-Cit-OH, we serve advanced industrial sectors that require reliable sourcing and integration of this specialty amino acid derivative. The following application scenarios reflect verified, real-world downstream uses within regulated production environments, focusing on the distinct functional role and operational requirements in each sector.

1. Peptide API Synthesis (Pharmaceutical Intermediates)

In the pharmaceutical industry, H-D-Cit-OH functions as an essential protected citrulline derivative during solid-phase peptide synthesis (SPPS) for advanced active pharmaceutical ingredient (API) manufacturing. It supports precise sequence assembly for therapeutic peptides requiring citrulline residues, contributing to the fidelity of APIs that target autoimmune and inflammatory disorders. Our material enters the process following standard coupling and deprotection protocols, maintaining traceability under GMP batch control through each step up to final API isolation and purification.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice (GMP) for Active Pharmaceutical Ingredients
• 21 CFR Part 210/211 US FDA cGMP, applicable to intermediates
• European Pharmacopoeia (Ph. Eur.), USP <788> (where applicable to residuals)
• ISO 9001 quality management integration for traceability

Typical usage ratio

• Mol. equivalent set relative to resin loading (0.9–1.1 eq per coupling step). Adjusted per targeted peptide sequence and resin substitution degree.

Downstream process integration

• Direct coupling to growing peptide chain on solid-phase resin during automated or manual SPPS cycle, prior to final cleavage and purification.

Final product types

• Peptide-based APIs for autoimmune, oncology, or metabolic disease therapeutics, including BPC-157, arginine-citrulline-based bioactives, and diagnostic peptides.

2. Diagnostic Peptide Synthesis (IVD Reagent Manufacture)

Clinical diagnostics manufacturers utilize H-D-Cit-OH as a non-proteinogenic amino acid for the preparation of synthetic antigens or immunoassay calibrators, such as anti-citrullinated peptide antibodies (ACPA) in rheumatoid arthritis kits. Compliance to IVD material standards is critical; our production supports traceable use from protected intermediate to final diagnostic-grade peptide, with integration into certified cleanroom peptide synthesis and purification lines.

Industry compliance standards

• ISO 13485:2016 for medical device and IVD manufacturing
• EN 13612 for performance evaluation of IVDs
• Directive 98/79/EC (IVDD) and its successor Regulation (EU) 2017/746 (IVDR)
• ISO 9001:2015 (ancillary input material quality)

Typical usage ratio

• Set by target peptide sequence; typically 1 eq. H-D-Cit-OH per desired citrulline insertion, with overall sequence concentration in the 0.1–2 mmol/g loading range for SPPS.

Downstream process integration

• Integration during the elongation phase of peptide synthesis targeting diagnostic epitope structure, followed by HPLC/MS quality release before IVD formulation.

Final product types

• ACPA synthetic peptides for rheumatoid arthritis test kits
• Peptide calibrators and controls for autoimmune disease diagnostics
• Reference standards for analytical method validation

3. Custom Peptide Manufacturing (CDMO Service Production)

Custom peptide contract development and manufacturing organizations (CDMOs) order H-D-Cit-OH for diverse biopharmaceutical projects requiring site-specific citrullination, especially where peptide structure-function relationships play a key role in immunology or cell signaling. Our batches, produced under extended in-process QC and supported by retest documentation, facilitate robust scale-up from mg to multi-kg lots, meeting custom project specifications for protected amino acid integration.

Industry compliance standards

• ICH Q9 Quality Risk Management for CDMO supply chains
• USP General Chapter <1047> (CDMO QC for peptides)
• ISO 22716 Good Manufacturing Practice (cosmetic peptides, where needed)
• Validated internal SOPs for incoming materials

Typical usage ratio

• Determined on a custom basis per project peptide sequence; generally 1 eq per citrullination position, with total input typically less than 0.5–5% w/w of total resin batch weight.

Downstream process integration

• Addition during peptide sequence assembly in dedicated CDMO reactors, incorporating orthogonal protection and specialized cleavage steps according to custom protocol.

Final product types

• Research-grade and GMP-grade custom peptides for academic, clinical, and preclinical use
• Modified peptides for cell signaling or immunology research
• Epitope-mapping libraries

4. Bioconjugation Peptide Intermediate Production (Therapeutic Conjugate Components)

Producers of antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs) integrate H-D-Cit-OH as an N-terminal or side-chain protected citrulline source to create enzymatically cleavable linkers or payload attachment sites. This application requires traceable supply and batch consistency to meet demanding release acceptance criteria, as conjugates must satisfy both biological performance and regulatory documentation for clinical manufacturing pipelines.

Industry compliance standards

• US FDA cGMP guidelines for bioconjugate manufacture (21 CFR Parts 210/211)
• ICH Q11 Development and Manufacture of Drug Substances
• USP General Chapter <1207> for container closure integrity (where applicable to peptide intermediates)
• Supplier qualification per customer QMS

Typical usage ratio

• Equivalent to designed citrulline content in linker-peptide, most often 1–3 molar equivalents per peptide fragment in linker payload; adjusted for scale-up from mg to multi-g batch.

Downstream process integration

• Incorporated during protected peptide linker assembly, ahead of conjugation to antibodies or small molecule drugs, with subsequent purification and conjugate characterization.

Final product types

• Cleavable peptide linker intermediates for ADCs and PDCs
• Payload attachment scaffolds for targeted drug delivery systems
• Enzyme substrate peptides for biological assays

5. Specialty Research Reagents (Biochemical R&D)

In academic and industrial biochemical R&D, H-D-Cit-OH provides a practical citrulline source for controlled modification or post-translational mimicry when tagging or probing peptide-based mechanisms in laboratory studies. Laboratories specify analytical documentation such as NMR and HPLC chromatograms while requiring flexible minimum order quantities and batch repeatability for reproducible bench-scale synthesis.

Industry compliance standards

• ISO 9001:2015 (research chemical quality systems)
• GLP (Good Laboratory Practice) for regulated R&D settings
• Guidance for Laboratory Chemicals (OECD GLP)

Typical usage ratio

• Directly proportionate to experimental peptide design requirements, typically 0.01–0.1 molar equivalents per synthesis cycle for in vitro research applications.

Downstream process integration

• Manual or automated synthesis workflow for custom peptide research, with in-process monitoring for side reaction control and peptide purity verification post-cleavage.

Final product types

• Synthetic peptides for biochemical/protein modification studies
• Mass spectrometry and proteomics standards
• Citrullinated peptides for enzyme activity assays